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Metformin is a widely used insulin-sensitizing drug, though its mechanisms are not fully understood. Metformin has been shown
to activate AMPK in skeletal muscle; however, its eﬀects on the inhibitor of κB kinaseβ (IKKβ) in this same tissue are unknown.
The aim of this study was to (1) determine the ability of metformin to attenuate IKKβ action, (2) determine whether changes in
AMPK activity are associated with changes in IKKβ action in skeletal muscle, and (3) examine whether changes in AMPK and IKKβ
function are consistent with improved insulin signaling. Lean and obese male Zuckers received either vehicle or metformin by oral
gavage daily for four weeks (four groups of eight). Proteins were measured in white gastrocnemius (WG), red gastrocnemius (RG),
and soleus. AMPK phosphorylation increased (P < .05) in WG in both lean (57%) and obese (106%), and this was supported
by an increase in phospho-ACC in WG. Further, metformin increased IκBα levels in both WG (150%) and RG (67%) of obese
rats, indicative of reduced IKKβ activity (P < .05), and was associated with reduced IRS1-pSer307 (30%) in the WG of obese rats
(P < .02). From these data we conclude that metformin treatment appears to exert an inhibitory influence on skeletal muscle IKKβ
activity, as evidenced by elevated IκBα levels and reduced IRS1-Ser307 phosphorylation in a fiber-type specific manner.
1. Introduction
Insulin resistance is considered a characteristic feature of
a clustering of diseases referred to often as the metabolic
syndrome [1]. Such associated pathologies include not only
cardiovascular disease but also Type II Diabetes Mellitus and,
more recently, inflammatory-related metabolic diseases. In
this regard, obesity is often associated with insulin resis-
tance, notably in skeletal muscle [2, 3]. This has immense
clinical and economic significance as obesity has reached
epidemic proportions not only in the US, but in Western
Society at large [4]. Although increased physical activity
and nutritional interventions have been used to reduce the
progression or reverse obesity (and hence improve insulin
action), it has often been met with limited success due
to low, long-term patient compliance. In addition, many
obese individuals do not posses the physiological capacity
for increased physical activity. These circumstances leave
pharmacological interventions as an attractive adjunct or
alternative therapeutic intervention for treating not only
obesity but also associated type II diabetes. Currently,
the insulin-sensitizing drug metformin, a member of the
biguanide drug class, is widely prescribed. Yet despite its
widespread prescription, its basic mechanism of action is
poorly understood, slowing the development of even more
eﬀective insulin-sensitizing molecules.
The link between obesity and insulin resistance can be
partly explained by the NF-κB pathway and its associated
upstream kinases, whose activity is stimulated as a result of
the chronic and excessive lipid circulation and accumulation
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in nonadipose tissue sites, a prominent feature of obesity
[5, 6]. Lipid accumulation in skeletal muscle has been
shown to be associated with insulin resistance [7], and
weight loss appears to reverse this eﬀect [8, 9]. Ectopic fat
deposition can lead to activation of the inhibitor of κB kinase
β (IKKβ) and induction of its downstream substrate, the
inflammatory transcription factor NF-κB [3]. Specifically,
NF-κB is sequestered in the cytoplasm in an inactive state
while complexed with the inhibitor protein called inhibitor
κBα (IκBα). Upon stimulation by IKKβ, which is itself
stimulated by both cytokines and lipids [10], IκBα is
phosphorylated and degraded, resulting in the liberation
of NF-κB, which migrates into the nucleus and activates
transcription of inflammatory cytokine genes. Interestingly,
in addition to activating NF-κB, IKKβ has also been shown
to directly phosphorylate serine312(Human)/307(rodent) on insulin
receptor substrate (IRS)-1, leading to a decrease in insulin
signal transduction [2, 11–13].
In contrast to the insulin-resistant eﬀects of excessive
IKKβ activity, AMP-activated protein kinase (AMPK), a
prominent metabolic enzyme, acts to improve insulin sen-
sitivity, potentially counter-acting the deleterious eﬀects
of lipid excess. Additionally, many commonly prescribed
antidiabetic medications, such as metformin and the thia-
zolidinediones, are known to increase AMPK activity [14,
15]. In the past few years, research has revealed the role
of AMPK as an inhibitor of IKKβ activity in certain cell
types. AMPK has been shown to inhibit both fatty acid-
and TNFα-induced increases in IKKβ activity in cultured
endothelial cells [16, 17], macrophages [18], and astrocytes
[19]. Furthermore, metformin treatment has also displayed
anti-IKKβ properties in the liver and has been shown to
prevent lipid-induced insulin resistance [20].
Inasmuch as skeletal muscle is the main consumer
of glucose in vivo, studying the eﬀects of metformin on
IKKβ activity in skeletal muscle, and the role of AMPK
in possibly mediating this response, holds great potential
for addressing the obesity-diabetes relationship in skeletal
muscle. Metformin has been shown to upregulate AMPK
activity in both human and rat skeletal muscle [15, 21]. Work
in endothelial cells and liver has shown that metformin can
reduce IKKβ activity, raising the possibility that activation of
AMPK may be a mechanism by which metformin improves
insulin sensitivity in skeletal muscle. Therefore, the aim
of this study was to (1) determine whether metformin
attenuates IKKβ activity in skeletal muscle of obese rats, (2)
determine whether changes in AMPK are associated with
reduced IKKβ activity in skeletal muscle, and (3) examine
whether a decrease in IKKβ activity coincides with reduced
phosphorylation of Ser307 on IRS1 in skeletal muscle and
whether this translates into increased glucose tolerance.
2. Materials and Methods
2.1. Materials. All antibodies used in this investigation were
obtained from commercial sources. Antirabbit monoclonal
IRS-1 IP antibody for immunoprecipitation was purchased
from Santa Cruz Biochtech (Santa Cruz, CA). IRS-1
and Phospho-IRS1 Ser307 antibodies were purchased from
Millipore (Billerica, MA). Antibodies for phospho-AMPK,
AMPK, phospho-ACC, and ACC were purchased from Cell
Signaling Technologies (Beverly, MA) and IκBα and actin
from Santa Cruz Biochtech (Santa Cruz, CA). Horseradish
peroxidase-conjugated antirabbit secondary antibodies were
purchased from Cell Signaling Technologies (Beverly, MA).
2.2. Animals and Housing. All protocols for animal use
were approved by the Animal Care and Use Committee at
East Carolina University. Lean and obese male Zucker rats
were obtained from Harlan (Indianapolis, IN) and were
housed under controlled temperature (23◦C) and lighting
(12 hours of light, 0600–1800 hours; 12 hours of dark; 1800–
0600 hours) with free access to water and standard rat
chow. Animals were fasted 10 hours before the oral glucose
tolerance tests (OGTTs).
2.3. Metformin Treatment and Oral Glucose Tolerance Testing.
Obese and lean Zucker rats were randomly assigned to
receive either control (saline) or metformin (320 mg/kg/day)
by daily gavage for four weeks (N = 8 per group) with the
final dose given 4 hours prior to sacrifice. On experimental
days, rats were anesthetized with 0.1 mL/100 g body wt of
a mixture containing 90 mg/mL ketamine and 10 mg/mL
xylazine. With blood flow intact, white gastrocnemius (WG),
red gastrocnemius (RG), and soleus muscles were harvested
from hind limbs. Samples were rapidly dissected, cleaned,
and frozen within seconds in liquid nitrogen and stored at
−80◦C until analysis.
2.4. Preparation of Skeletal Muscle Homogenates. Frozen
muscle samples (50–80 mg) were homogenized in ice-cold
lysis buﬀer 50 mM HEPES, 50 mM Na+ pyrophosphate,
100 mM Na+ fluoride, 10 mM EDTA, 10 mM Na+ orthovana-
date, 1% Triton X-100, and protease and phosphatase (1 and
2) inhibitor cocktails (Sigma, St. Louis, MO). Homogenates
were sonicated for 10 seconds then rotated for 2 hours at 4◦C.
After centrifugation for 25 minutes at 14,000 g, supernatants
were extracted and protein content was detected using a
BCA protein assay (Pierce, Rockford, IL) and individual
homogenate volumes were separated into 50 μg of protein
before being frozen in liquid nitrogen and stored at −80◦C
until used for immunoblotting.
2.5. Immunoblotting. For IRS-1, homogenates were sub-
jected to 10 μL IRS-1 monoclonal IP antibody (Santa Cruz
Biotech, Santa Cruz, CA) overnight then coupled to protein
A sepharose beads and rotated for 2 hours (Amersham
Biosciences, Uppsala Sweden) and eluted with sample buﬀer.
Samples were separated by SDS-PAGE using 7.5% or 10%
Tris·HCl gels and then transferred to PVDF membranes
for probing by appropriate antibodies. Following incuba-
tion with primary antibodies, blots were incubated with
appropriate horseradish peroxidase-conjugated secondary
antibodies. Horseradish peroxidase activity was assessed with
ECL solution (Thermo Scientific, Rockford, IL), and exposed
to film. The image was scanned and band densitometry was
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Figure 1: The eﬀect of daily vehicle (open bars) or metformin (filled bars) gavage on AMPK (a) and ACC (b) phosphorylation in soleus,
RG, and WG. ∗P < .05. AU: arbitrary units.
assessed with Gel Pro Analyzer software (Media Cybernetics,
Silver Spring, MD). Equal loading of proteins was ensured
by probing for actin. Content of phospho-proteins (using
phospho-specific antibodies) was calculated from the density
of the band of the phospho-protein divided by the density of
the total protein using the appropriate antibody.
2.6. Statistical Analysis. All data are presented as means ±
SEM. Two-way analysis of variance (ANOVA) was used to
compare group and treatment (SPSS, Chicago, IL). Where
an interaction was observed, post hoc analysis (Bonferroni
and Tukey’s HSD) was used to determine significance.
Correlation analysis was performed by the Pearson product-
moment method. Significance level was established a priori
at P ≤ .05.
3. Results
3.1. Metformin and AMPK Activation. AMPK activation was
determined by measuring phosphorylation of AMPK and
its substrate acetyl-CoA-carboxylase (ACC) while controlling
for total levels of both proteins. No diﬀerence in AMPK
phosphorylation was observed between lean and obese
controls in any of the three muscles. Moreover, chronic
metformin treatment did not significantly aﬀect AMPK
phosphorylation in RG or soleus in neither the lean nor
obese rodents (Figure 1(a)), and this was further evident by
no change in levels of pACC in these muscles (Figure 2(b)).
In contrast, metformin resulted in a significant increase in
both phosphorylation of AMPK and ACC in both the lean
(57% for pAMPK and 525% for pACC) and obese (106%
for pAMPK and 710% for pACC) rats in WG compared with
control animals (Figures 1(a) and 1(b); P < .05).
3.2. Metformin and IκBα. Inasmuch as metformin has been
shown to reduce IKKβ activity in various tissues, IκBα was
measured as an indicator of IKKβ action. Several groups
have shown that IκBα levels are closely associated with
IRS1-Ser phosphorylation and IKKβ activity [22–24]. No
diﬀerences in IκBα levels were observed between controls
animals in either soleus or RG and chronic metformin
treatment resulted in no significant eﬀect in soleus from the
lean or obese animals (Figure 2(a)). However, IκBα levels
were significantly lower in WG of obese when compared with
lean. Further, metformin treatment increased IκBα levels
in both RG and WG of obese animals by 67% and 150%,
respectively, to a level similar to that seen in lean (P < .05 for
RG, P < .005 for WG). When combining all data from WG,
IκBα showed a strong correlation to AMPK phosphorylation
(r = 0.755,P < .005; Figure 2(b)).
3.3. IRS1-Serine307 Phosphorylation. Due to the implicated
role of serine phosphorylation of IRS1 in inhibiting insulin
signaling, we measured IRS1-pS307 and controlled for total
IRS1. Similar to our observation with IκBα, there was no sig-
nificant eﬀect of treatment on soleus pSer307 levels in either
lean or obese rodents (Figure 3(a)). Similarly, no diﬀerences
were observed in RG, although pSer307 in obese tended to
be lower in the metformin-treated versus control animals
(P = .061). In contrast, pSer307 levels in control animals
were significantly higher in obese WG compared with lean
(P < .05). Moreover, pSer307 levels were significantly reduced
(30%) with metformin treatment in WG from obese rodents
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Figure 2: The eﬀect of vehicle (open bars) or metformin (filled bars) on IκBα levels in soleus, RG, and WG (a) and the correlation between
AMPK and IκBα (b) in WG from obese and lean male Zucker rats. Equal loading of proteins was ensured by probing for actin. P < .05 for
vehicle versus metformin treatment within same phenotype (∗) and lean versus obese within a given treatment (#). AMPK activation and
IκBα levels were significantly correlated in WG (r = 0.755, P < .005).
(P < .05). Inasmuch as IκBα and pSer307 appeared to follow
similar trends in WG, we performed a correlation analysis
between the two variables. When comparing pSer307 and
IκBα in all groups, no significant correlation was observed
(r = −0.536,P = .067; data not shown). However, in
WG alone the correlation between pSer307and IκBα reached
significance (r = −0.789,P < .01; Figure 3(b)), indicating an
inverse relationship in WG.
4. Discussion
The main finding of the present study is that the beneficial
eﬀects of metformin treatment on glucose tolerance in obese,
insulin-resistant rodents is associated not only with an eleva-
tion in AMPK action, but also IκBα levels in WG from obese,
insulin-resistant rats. This finding is an indication of reduced
IKKβ activity and suggests that metformin treatment is able
to reduce IKKβ activity and restore IκBα protein levels within
the muscle. Moreover, these observations are associated with
improved insulin signaling, as evidenced by reduced IRS1-
pSer307 levels. Lastly, levels of IκBα and IRS1-Ser307 were
significantly and inversely correlated with metformin-treated
obese rats, but only in white muscle, suggesting a fiber-type
specific action of metformin on the IKKβ signaling pathway.
Recent work has supported the role of IKKβ as an
inhibitor of insulin action that results in insulin resistance.
In particular, salicylate is known to inhibit the activity of
IKKβ, and pretreatment of salicylate in lipid-infused rats
rescues glucose tolerance back to similar levels seen in
control rats when compared with lipid infusion alone [25].
Further, Yuan et al. [13] showed that Ikkβ+/− mice have
lower fasting glucose and insulin concentrations compared
to Ikkβ+/+ littermates when on high-fat diets. Additionally,
IKKβ KO mice experience no decrement in insulin sensitivity
in response to lipid infusion compared to control mice
[26]. Collectively, these findings demonstrate that activation
of IKKβ is associated with a negative impact on insulin
sensitivity. Given these findings and those from other
groups demonstrating significant correlations between IKKβ
activity, IκBα levels, and IRS1-Ser307 phosphorylation [9, 22–
24], we are optimistic that the surrogate outcomes used
to determine IKKβ action, namely, IκBα and IRS1-Ser307
phosphorylation, IKKβ’s immediate downstream eﬀectors,
adequately reflect IKKβ action.
In addition to IKKβ, other lipid-sensitive serine kinases
have been implicated in phosphorylating IRS1-Ser312. In par-
ticular, certain protein kinase C (PKC) isoforms have been
shown to be associated with changes in insulin signaling in a
similar manner to IKKβ and some groups present evidence
of it being indispensable in potentiating the lipid-induced
decay in the insulin signal [23, 27–29]. In particular, in
addition to observing a reduction in IκBα levels, Itani et al.
[23] observed an increase in membrane-associated PKCβ
in the muscle of patients during an acute lipid infusion.
However, we found no diﬀerences in membrane-associated
PKCβ levels when comparing animals or treatment (data
not shown). The discrepancy between these data is possibly
due to the diverse conditions and models (e.g., acute lipid
infusions versus diet-induced obesity, human versus rodent).
In support of our findings, Huang et al. [30] demonstrated
that muscle PKCβ levels did not diﬀer between control and
diet-induced obese mice.
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Figure 3: The eﬀect of vehicle (open bars) or metformin (filled bars) on IRS1-pSer307in soleus, RG, and WG (a) and the correlation between
IκBα and IRS1-pSer307(b) in WG from obese and lean Zucker male rats. P < .05 for vehicle versus metformin treatment within same
phenotype (∗) and lean versus obese within a given treatment (#). IκBα and IRS1-pSer307 levels were significantly related in WG (r =
−0.789,P < .01).
Contrary to the reduced insulin sensitivity associated
with IKKβ activity, AMPK plays a key role in improv-
ing glucose handling and increasing insulin action. In
muscles from sedentary rats, coincubation with insulin
and the compound 5-aminoimidasole-4-carboxamide-1-β-
D-ribofuranoside (AICAR; an AMP-mimetic and AMPK
activator) has been shown to induce a twofold greater glucose
uptake compared to insulin alone [31]. Similarly, AICAR-
perfused rat hindlimbs have been shown to increase glucose
uptake compared with controls [32].
Research investigating the novel role of AMPK as a
mediator in IKKβ’s ability to inhibit IRS-1 function in
endothelial cells has revealed that AMPK inhibits both fatty
acid- and TNFα-induced increases in NF-κB in cultured
endothelial cells [16]. When endothelial cell cultures were
incubated with palmitate, inflammatory markers increased,
but this response was attenuated in the presence of AICAR.
Moreover, AICAR acted to prevent NF-κB activation in
the presence of TNFα. This provides strong evidence in
support of a role for AMPK in attenuating inflammation and
associated cellular metabolic dysfunction. Additionally, met-
formin, which leads to AMPK activation, dose-dependently
inhibits TNFα-induced NF-κB activation, whereas blocking
signaling through AMPKα1 (via small interfering RNA)
attenuates metformin- and AICAR-induced inhibition of
NF-κB activation by TNFα, further supporting a role for
AMPK attenuating the inflammation response [17]. A sim-
ilar relationship was explored in macrophages [33], where
treatment of RAW264.7 cells with berberine, a known AMPK
activator, was shown to inhibit expression of inflammatory
genes including IL-1β and MCP-1 via an AMPK-dependent
mechanism.
Research involving metformin has also displayed anti-
IKKβ properties in the liver. Cleasby et al. [20] observed
elevated levels of IκBα in liver from metformin-treated
rodents, providing indirect evidence that AMPK may be
serving as an IKKβ inhibitor in an insulin sensitive tissue.
These findings provide the rationale for exploring the
potential role of AMPK as an IKKβ inhibitor in skeletal
muscle inasmuch as muscle represents the main site of
insulin-dependent glucose uptake.
The idea of AMPK attenuating inflammatory activity in
skeletal muscle has only recently been investigated and, due
to a scarcity of data, a consensus has yet to be reached.
For example, Steinberg et al. [34] observed that muscle
cells with constitutively active AMPK were protected from
TNFα-induced suppression of insulin-stimulated glucose
uptake (TNFα has been shown to elicit an increase in IKKβ
activity). In ob/ob mice, it was found that AMPK activity was
significantly reduced compared with lean controls and that
TNFα neutralization in ob/ob mice restored AMPK activity
to that of lean controls. Furthermore, obese mice exhibited
reduced fatty acid oxidation, a defect that was not observed
following TNFα neutralization. Lastly, ob/ob mice lacking a
functional TNFα receptor (TNF−/−) enjoy greater insulin
sensitivity than control ob/ob mice. It was observed that
AMPK activity was higher in obese TNF−/− relative to obese
controls. Whereas the evidence provided by Steinberg et al.
[34] places inflammatory mediators upstream of AMPK, the
work by Hattori et al. [17] oﬀers the opposite perspective—
that AMPK inhibits NF-κB pathway activity. Moreover, the
observations of the current study extend the work by Hattori
et al. [17] in that we provide evidence that AMPK may
attenuate IKKβ action in skeletal muscle. Specifically, we
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observed an increase in AMPK phosphorylation, an increase
in IκBα levels (suggesting reduced IKKβ activity), and,
finally, reduced levels of IRS1-pSer307 in white muscle from
metformin-treated obese rats.
In contrast, Ho et al. [35] explored the eﬀects of AICAR-
stimulated AMPK activation in rats in vivo and found no
reduction in IKKβ phosphorylation 60 minutes following an
intraperitoneal injection of AICAR despite a robust increase
in AMPK activity in skeletal muscle. Further, they did not
observe any change in IKKβ phosphorylation in isolated rat
EDL muscles treated with AICAR. These findings appear
to indicate that AMPK does not directly regulate IKKβ
activity; however, the acute nature of the study design must
be considered. The findings of the current study utilized a
chronic treatment intervention and support the possibility
that metformin-mediated activation of AMPK attenuates
IKKβ activity, as has been established in hepatic tissue [20].
Interestingly, metformin-induced activation of AMPK
occurs in the absence of any changes in ATP/ADP ratio,
indicating that a decrease in cellular energy charge is not the
link between metformin and AMPK activation [36]. In this
regard, synergistic or independent mechanisms should also
be considered. For example, metformin has also been shown
to partially inhibit mitochondrial complex I and subsequent
free radical production [37], raising the possibility that
an additional, unique eﬀect of metformin in improving
IκBα and IRS1-pSer307 levels may be related to its eﬀects
on mitochondrial function in addition to that of AMPK
activation. An association between free radical production,
IKKβ activity, and insulin sensitivity has been established and
might prove to be a fruitful area of investigation on this topic.
It is noteworthy that we observed neither an increase in
AMPK activity nor a reduction in IKKβ activity or IRS1-
pSer307 in soleus with metformin treatment. Similarly, no
diﬀerences were noted in either AMPK or IRS1-pSer307 levels
in RG, although IκBα levels increased in obese RG with met-
formin treatment. The singular change in IκBα levels without
an accompanying reduction in IRS1-Ser307 phosphorylation
in RG was unexpected, though the comparison of IRS1-
pSer307 levels between metformin-treated and control obese
animals did approach statistical significance (P = .061).
Future studies seem warranted then to determine if both
statistical and physiological significance would be realized
in red muscle following a longer treatment time as would
be expected in human subjects under chronic metformin
prescription.
In contrast to the observations in soleus and RG, AMPK,
IκBα, and IRS1-pSer307 levels were all aﬀected by chronic
metformin treatment in WG from the obese rats. Specifically,
metformin treatment increased AMPK activity and was
associated with both an increase in IκBα protein levels
and a reduction in IRS1-pSer307. In accordance with these
findings, it should be recognized that other investigators
have noted diﬀerences in the IKKβ signaling pathway
between muscle fiber types. For example, Bhatt et al. [38]
observed a reduction in IκBα levels with diet-induced obesity
in rat skeletal muscle in a fiber-type dependent manner.
Specifically, obesity was associated with decreased levels
of IκBα in superficial vastus (white, fast twitch-glycolytic),
whereas the soleus (red, slow twitch-oxidative) appeared to
be protected from such an eﬀect. Additionally, Iglesias et al.
[39] observed an AICAR-induced improvement in glucose
uptake in white muscle that was not evident red muscle.
Inasmuch as metformin may exert its action by altering
mitochondrial function, it is possible that given red muscle’s
prevalence of mitochondria, a greater metformin dose is
required to elicit the same response as observed in white
muscle.
5. Conclusion
In summary, these findings demonstrate that IRS1-Ser307
phosphorylation is elevated in certain muscle types of obese,
highly insulin resistant Zucker rats. Moreover, metformin
treatment is associated with increased AMPK function and
IκBα levels, at least in white muscle. These findings are novel,
in that they oﬀer support for the hypothesis that AMPK
may influence IKKβ action. Indeed, under the experimental
conditions present in the current study, AMPK appears to
exert an inhibitory eﬀect on IKKβ in a fiber-type dependent
manner, which contributes to the change in muscle insulin
signaling. Future studies investigating dose and treatment
time for Metformin seem warranted when considering
potential eﬀects on the IKKβ signaling pathway in muscles
of red fiber type composition.
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